A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward ß-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.

Stanislaus, Shanaka; Hecht, Randy; Yie, Junming; Hager, Todd; Hall, Michael; Spahr, Chris; Wang, Wei; Weiszmann, Jennifer; Li, Yang; Deng, Liying; Winters, Dwight; Smith, Stephen; Zhou, Lei; Li, Yuesheng; Véniant, Murielle M; Xu, Jing

Stanislaus, Shanaka; Hecht, Randy; Yie, Junming; Hager, Todd; Hall, Michael; Spahr, Chris; Wang, Wei; Weiszmann, Jennifer; Li, Yang; Deng, Liying; Winters, Dwight; Smith, Stephen; Zhou, Lei; Li, Yuesheng; Véniant, Murielle M; Xu, Jing.

Afiliação

Stanislaus S; Department of Cardiometabolic Disorders, Amgen Inc., Thousand Oaks, California 91320.
Hecht R; Department of Biologics, Amgen Inc., Thousand Oaks, California 91320.
Yie J; Department of Cardiometabolic Disorders, Amgen Inc., Thousand Oaks, California 91320.
Hager T; Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California 91320.
Hall M; Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California 91320.
Spahr C; Department of Biologics, Amgen Inc., Thousand Oaks, California 91320.
Wang W; Department of Biologics, Amgen Inc., Thousand Oaks, California 91320.
Weiszmann J; Department of Cardiometabolic Disorders, Amgen Inc., Thousand Oaks, California 91320.
Li Y; Amgen Inc., South San Francisco, California 94080.
Deng L; Department of Cardiometabolic Disorders, Amgen Inc., Thousand Oaks, California 91320.
Winters D; Amgen Inc., South San Francisco, California 94080.
Smith S; Department of Cardiometabolic Disorders, Amgen Inc., Thousand Oaks, California 91320.
Zhou L; Department of Biologics, Amgen Inc., Thousand Oaks, California 91320.
Li Y; Department of Biologics, Amgen Inc., Thousand Oaks, California 91320.
Véniant MM; Department of Medical Science, Amgen Inc., Thousand Oaks, California 91320.
Xu J; Department of Biologics, Amgen Inc., Thousand Oaks, California 91320.

Endocrinology ; 158(5): 1314-1327, 2017 05 01.

Article em En | MEDLINE | ID: mdl-28324011

Assuntos

Fármacos Antiobesidade/uso terapêutico; Diabetes Mellitus Experimental/tratamento farmacológico; Fatores de Crescimento de Fibroblastos/uso terapêutico; Fragmentos Fc das Imunoglobulinas/uso terapêutico; Proteínas de Membrana/metabolismo; Obesidade/tratamento farmacológico; Células 3T3-L1; Animais; Fármacos Antiobesidade/síntese química; Fármacos Antiobesidade/metabolismo; Diabetes Mellitus Experimental/metabolismo; Modelos Animais de Doenças; Estabilidade de Medicamentos; Fatores de Crescimento de Fibroblastos/genética; Fatores de Crescimento de Fibroblastos/metabolismo; Células HEK293; Meia-Vida; Humanos; Fragmentos Fc das Imunoglobulinas/genética; Fragmentos Fc das Imunoglobulinas/metabolismo; Proteínas Klotho; Macaca fascicularis; Masculino; Camundongos; Camundongos Endogâmicos C57BL; Mutação; Obesidade/metabolismo; Ligação Proteica; Engenharia de Proteínas/métodos; Proteólise; Proteínas Recombinantes de Fusão/genética; Proteínas Recombinantes de Fusão/metabolismo; Proteínas Recombinantes de Fusão/uso terapêutico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fragmentos Fc das Imunoglobulinas / Fármacos Antiobesidade / Diabetes Mellitus Experimental / Fatores de Crescimento de Fibroblastos / Proteínas de Membrana / Obesidade Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google